Long End of the Stick

Sustainable and increasingly focused, mid-sized vaccines companies are leading the way in European biotech, catalyzed by fears of bioterrorism and a re-emerging belief that prevention trumps cure, both practically and pharmaco-economically.

As many biotechnology companies struggle to progress pipelines and deal with product setbacks in the face of dwindling cash reserves, Europe's vaccines plays are navigating today's difficult waters more successfully.

Vaccine companies, the perennial middle child of the life sciences, have increased margins on their products, consolidated effectively, jettisoned dead...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Deal-Making

Deals Shaping The Industry, August 2024

 
• By 

<p>Executive Summary</p> <p>An interactive look at pharma, medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker</p>

Innovative Drugs: China Gains Deals, But Financing Amounts Drop

 
• By 

China has seen a “milestone year for the overseas launch of domestically produced innovative drugs.”

Deal Volume Up, Value Down During The First Half

 
• By 

Without a mega-merger like 2023’s Pfizer/Seagan takeout, M&A deals grew smaller during the first half of 2024, while volume rose. In alliance deals, H1 2024 activity somewhat mirrored activity from H1 2023.

Deals Shaping The Industry, July 2024

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during July 2024. Data courtesy of Biomedtracker.

More from In Vivo

Vigya test infogram

add a desc test

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.